Lanreotide ( DrugBank: Lanreotide )

4 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
67	多発性嚢胞腎	6
73	下垂体性TSH分泌亢進症	1
85	特発性間質性肺炎	1
298	遺伝性膵炎	1

67. 多発性嚢胞腎

臨床試験数 : 216 / 薬物数 : 219 - (DrugBank : 50) / 標的遺伝子数 : 39 - 標的パスウェイ数 : 151

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02127437 (ClinicalTrials.gov)	September 19, 2014	2/4/2014	Lanreotide In Polycystic Kidney Disease Study	Lanreotide In Polycystic Kidney Disease Study	Autosomal Dominant Polycystic Kidney Disease (ADPKD	Drug: Lanreotide;Drug: saline	Assistance Publique - Hôpitaux de Paris	IPSEN pharmaceutical company, Boulogne-Billancourt, France	Completed	18 Years	N/A	All	159	Phase 3	France
2	NCT01616927 (ClinicalTrials.gov)	June 2012	6/6/2012	Study of Lanreotide to Treat Polycystic Kidney Disease	The DIPAK 1 Study: A Randomised, Controlled Clinical Trial Assessing the Efficacy of Lanreotide to Halt Disease Progression in ADPKD	Autosomal Dominant Polycystic Kidney Disease (ADPKD)	Drug: Lanreotide	University Medical Center Groningen	Leiden University Medical Center;Erasmus Medical Center;Radboud University	Active, not recruiting	18 Years	60 Years	All	300	Phase 3	Netherlands
3	EUCTR2011-005017-37-NL (EUCTR)	30/05/2012	21/05/2012	To investigate the effect of Lanreotide on renal function decline in ADPKD patients	A randomised, controlled clinical trial assessing the efficacy ofLanreotide to halt disease progression in ADPKD - The DIPAK 1 Study	First, to demonstrate whether Lanreotide attenuates progression of the renal phenotype in ADPKD patients as measuredby change in rate of renal function decline and change in renal volume. Second, to demonstrate whether Lanreotidemodifies progression of the liver phenotype in the subset of ADPKD patients with moderate to severe polycystic liverdisease as measured by change in liver volume. MedDRA version: 14.1;Level: LLT;Classification code 10023433;Term: Kidney polycystic;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]	Trade Name: Somatuline Autogel Product Name: Lanreotide Product Code: BIM 23014 INN or Proposed INN: Lanreotide Other descriptive name: LANREOTIDE ACETATE	DIPAK Consortium	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Netherlands
4	NCT01354405 (ClinicalTrials.gov)	May 2011	13/5/2011	Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE)	The Effect of Lanreotide on Volume of Polycystic Liver and Kidney in Autosomal Dominant Polycystic Kidney Disease	Polycystic Liver Disease	Drug: Lanreotide	Radboud University	Ipsen	Completed	18 Years	70 Years	Both	43	N/A	Netherlands
5	NCT00771888 (ClinicalTrials.gov)	April 2008	13/10/2008	Open-Label Extension of LOCKCYST Trial	Open-Label Extension of the LOCKCYST Trial, LOCKCYST: Long Acting Lnareotide as as Volume Reducing Treatment of Polycystic Livers	Polycystic Liver Disease;Hepatomegaly;Liver Diseases;Polycystic Kidney;Autosomal Dominant	Drug: lanreotide	Radboud University	Ipsen	Active, not recruiting	18 Years	88 Years	Both	54	Phase 2/Phase 3	Belgium;Netherlands
6	NCT00565097 (ClinicalTrials.gov)	October 2007	28/11/2007	Lanreotide as Treatment of Polycystic Livers	Long-Acting Lanreotide as a Volume Reducing Treatment of Polycystic Livers	Polycystic Liver Disease;Hepatomegaly;Liver Diseases;Polycystic Kidney, Autosomal Dominant	Drug: Placebo;Drug: Lanreotide	Radboud University	Ipsen	Completed	18 Years	88 Years	Both	38	Phase 2/Phase 3	Belgium;Netherlands

先頭へ

73. 下垂体性TSH分泌亢進症

臨床試験数 : 1 / 薬物数 : 3 - (DrugBank : 2) / 標的遺伝子数 : 0 - 標的パスウェイ数 : 0

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-JapicCTI-173772	22/1/2018	15/11/2017	Phase 3 Study of ITM-014 in patients with thyroid-stimulating hormone-secreting pituitary adenoma	Phase 3, Open-label Study of ITM-014 in patients with thyroid-stimulating hormone-secreting pituitary adenoma	TSH-secreting pituitary adenoma	Intervention name : Lanreotide Acetate INN of the intervention : Lanreotide Dosage And administration of the intervention : Deep subcutaneous administration of 60 mg, 90 mg or 120 mg of lanreotide once every 4 weeks. Control intervention name : - INN of the control intervention : - Dosage And administration of the control intervention : -	Teijin Pharma Limited	NULL	complete	20		BOTH	8	Phase 3	Japan

85. 特発性間質性肺炎

臨床試験数 : 598 / 薬物数 : 435 - (DrugBank : 116) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 210

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2011-003687-78-IT (EUCTR)	21/02/2012	05/03/2012	Lanreotide Autogel for the treatment of patients with Idiopathic Pulmonary Fibrosis (IPF)	Lanreotide Autogel for the treatment of patients with Idiopathic Pulmonary Fibrosis (IPF) - IPF/LANREOTIDE/2011-01	Idiopathic Pulmonary Fibrosis MedDRA version: 14.1;Level: PT;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]	INN or Proposed INN: LANREOTIDE ACETATE Product Name: Gallium68-Dota-Noc Product Code: NA INN or Proposed INN: NA Other descriptive name: NA	AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Italy

298. 遺伝性膵炎

臨床試験数 : 98 / 薬物数 : 180 - (DrugBank : 57) / 標的遺伝子数 : 53 - 標的パスウェイ数 : 142

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2009-016082-29-BE (EUCTR)	10/03/2010	25/11/2009	Role of Lanreotide in the Management of Paraduodenal Pancreatitis - LPP	Role of Lanreotide in the Management of Paraduodenal Pancreatitis - LPP	Paraduodenal pancreatitis MedDRA version: 12.1;Level: LLT;Classification code 10009093;Term: Chronic pancreatitis	Trade Name: Somatuline Autogel 90 mg Other descriptive name: LANREOTIDE ACETATE	Erasme hospital	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	60		Belgium

先頭へ